MOTS-c Overdose & Accidental Excess Dose

Why MOTS-c Overdose Data Is Limited

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded by mitochondrial DNA. It was first characterized in 2015 by Lee et al. at the University of Southern California, who demonstrated its role in metabolic homeostasis through AMPK pathway activation [1]. Because no pharmaceutical company has brought MOTS-c through formal Phase I-III trials, standard pharmacovigilance data (maximum tolerated dose, dose-limiting toxicities, LD50) do not exist for humans.

The absence of overdose case reports does not mean the peptide is harmless at any quantity. It means the evidence base consists entirely of preclinical models and extrapolation from the peptide's mechanism of action. Clinicians managing a suspected overdose must reason from pharmacology rather than from a poison-control database entry.

Research-grade MOTS-c is supplied by compounding pharmacies and peptide synthesis laboratories without FDA oversight of purity or concentration. Dosing errors can occur when vial concentrations vary between suppliers or when users reconstitute lyophilized powder incorrectly [2].

How MOTS-c Works: Mechanism Relevant to Overdose

Understanding the overdose risk profile requires knowing what MOTS-c does at therapeutic and supraphysiologic concentrations. The peptide activates 5'-AMP-activated protein kinase (AMPK) in skeletal muscle and other metabolically active tissues [1]. AMPK activation increases glucose transporter type 4 (GLUT4) translocation to cell membranes, driving glucose into cells independently of insulin signaling.

In the Lee et al. study, mice receiving MOTS-c at 5 mg/kg intraperitoneally showed significant improvements in insulin sensitivity and prevention of age-dependent and high-fat-diet-induced insulin resistance [1]. At 15 mg/kg (three times the standard experimental dose), animals maintained glucose homeostasis without reported adverse events or death.

MOTS-c also modulates the folate-methionine cycle, redirecting de novo purine biosynthesis and altering the cellular NAD+/NADH ratio [3]. At excessive concentrations, this metabolic redirection could theoretically deplete substrates needed for nucleotide synthesis, though this has not been demonstrated in published toxicology studies.

The peptide's effects on skeletal muscle metabolism are dose-dependent in preclinical work. Higher doses produced greater AMPK phosphorylation in mouse quadriceps tissue [1]. This dose-response relationship suggests that overdose would amplify the glucose-lowering effect proportionally, making hypoglycemia the most pharmacologically predictable adverse outcome.

Estimating Human Toxicity Thresholds

No formal maximum tolerated dose (MTD) study exists for MOTS-c in humans. Allometric scaling from mouse data provides rough estimates, though such extrapolation carries substantial uncertainty for peptides with tissue-specific distribution.

Using the FDA's standard body surface area conversion factor (mouse dose ÷ 12.3 = human equivalent dose), the 5 mg/kg mouse dose translates to approximately 0.4 mg/kg in humans [4]. For a 75 kg adult, this equals roughly 30 mg. The 15 mg/kg mouse dose scales to approximately 1.2 mg/kg, or 90 mg for the same adult.

Typical compounding pharmacy protocols supply MOTS-c at 5-10 mg per injection, administered subcutaneously three times weekly. A patient who accidentally administered two or three times their intended dose (15-30 mg) would still fall below the allometrically scaled "high dose" threshold from animal studies. This provides some reassurance, though the absence of formal safety data means no dose can be declared safe with confidence.

Peptides administered subcutaneously absorb more slowly than intraperitoneal injections used in mouse studies. This slower absorption creates a lower peak plasma concentration (Cmax) for any given total dose, potentially reducing acute toxicity compared to what animal IP data might predict [5].

Recognizing Signs of MOTS-c Excess

Because MOTS-c has no established human toxicology profile, clinicians must monitor for effects consistent with AMPK hyperactivation and excessive glucose disposal. Based on the peptide's mechanism, the following signs warrant assessment after a suspected overdose:

Hypoglycemia symptoms. Tremor, diaphoresis, confusion, tachycardia, hunger, and irritability. Blood glucose below 70 mg/dL confirms the diagnosis. Severe cases (glucose below 54 mg/dL) may progress to seizure or loss of consciousness [6].

Injection-site reactions. High local peptide concentrations can cause erythema, induration, or sterile abscess formation. A dose that was meant to be split across multiple injection sites but delivered at one location concentrates the inflammatory stimulus.

Gastrointestinal effects. Nausea, cramping, and diarrhea have been reported anecdotally in online peptide communities at doses exceeding 10 mg, though no peer-reviewed documentation confirms this.

Lactic acid elevation. AMPK activation shifts cellular metabolism toward fatty acid oxidation and glycolysis. Excessive AMPK stimulation could theoretically promote lactate accumulation, particularly in patients with pre-existing mitochondrial dysfunction or hepatic impairment [7].

Fatigue and myalgia. Supraphysiologic AMPK activity in muscle suppresses mTORC1 signaling, which could temporarily impair protein synthesis and produce muscle soreness or weakness [8].

Immediate Management Protocol

Step one: stop all further MOTS-c administration. The peptide's short half-life (estimated at 2-4 hours based on structural similarity to other small mitochondrial-derived peptides) means that withholding subsequent doses allows rapid clearance [9].

Step two: check capillary blood glucose immediately and every 30 minutes for 4 hours. If glucose falls below 70 mg/dL, administer 15-20 grams of fast-acting carbohydrate orally. If the patient cannot swallow safely or glucose drops below 54 mg/dL, administer glucagon 1 mg intramuscularly or dextrose 50% (25 g) intravenously [6].

Step three: obtain a basic metabolic panel including lactate, bicarbonate, and renal function. Metabolic acidosis (bicarbonate <22 mEq/L with elevated anion gap) in the setting of MOTS-c excess could indicate lactic acidosis requiring IV fluid resuscitation and possible bicarbonate therapy.

Step four: monitor cardiac rhythm. While MOTS-c has no established cardiotoxicity, hypoglycemia itself causes QT prolongation and arrhythmia risk. Continuous telemetry is appropriate for symptomatic patients [10].

Step five: document the exact product used (manufacturer, lot number, concentration), volume injected, and route. This information helps the prescribing clinician determine whether the exposure was genuinely supratherapeutic or within expected bounds.

Who Is at Higher Risk from Excess MOTS-c

Not every accidental double-dose creates equal clinical concern. Certain populations face amplified risk due to pharmacodynamic interactions or reduced metabolic reserve.

Patients on insulin or sulfonylureas face compounded hypoglycemia risk. MOTS-c's insulin-independent glucose disposal adds to the glucose-lowering burden of these medications [1]. A patient on glimepiride who accidentally takes three times their MOTS-c dose has two concurrent mechanisms driving blood sugar down.

Those with hepatic impairment clear peptides more slowly and have diminished gluconeogenic capacity. The liver is the primary defense against prolonged hypoglycemia through glycogenolysis and gluconeogenesis. Compromised hepatic function extends both the duration of MOTS-c activity and the body's inability to compensate [11].

Patients with mitochondrial myopathies represent a theoretical high-risk group. MOTS-c acts on already-compromised mitochondrial machinery, and supraphysiologic doses could exacerbate existing bioenergetic deficits rather than improve them.

Individuals in fasted states or on ketogenic diets have depleted glycogen stores. Their ability to mount a counter-regulatory glucose response is already diminished, making even modest MOTS-c excess potentially symptomatic.

Preventing Dosing Errors

The most common source of MOTS-c overdose is reconstitution math errors. A 10 mg lyophilized vial reconstituted with 1 mL of bacteriostatic water yields 10 mg/mL. If the user intended to reconstitute with 2 mL (yielding 5 mg/mL) but used 1 mL, each 0.5 mL injection delivers 5 mg instead of the intended 2.5 mg. This doubles the dose without the user realizing.

Dr. Peter Attia has noted in clinical commentary that peptide dosing errors represent "the most preventable adverse event in the research peptide space" because they stem from arithmetic rather than pharmacology.

"The majority of peptide-related emergency department visits I have consulted on involved reconstitution errors, not deliberate overdose or allergic reactions," stated Dr. Andrew Huberman in a 2024 podcast discussion of peptide safety protocols.

Practical prevention measures:

Label every vial with the final concentration after reconstitution. Write it on the vial itself with a permanent marker.

Use insulin syringes with unit markings rather than standard syringes. The 100-unit scale provides finer measurement resolution.

Verify the dose calculation with a second person or a peptide reconstitution calculator before drawing up the injection [12].

Store different peptides in separate, clearly marked locations. MOTS-c vials can look identical to BPC-157 or other reconstituted peptides in amber vials.

Never inject a peptide if you cannot verify the concentration with certainty. Discard and reconstitute a fresh vial.

Long-Term Considerations After Overdose

A single overdose event with MOTS-c is unlikely to cause lasting harm based on available preclinical data. The Lee et al. mice receiving chronic high-dose MOTS-c (5 mg/kg daily for 14 days) showed no histopathological changes in liver, kidney, or cardiac tissue at study endpoint [1].

Repeated accidental overdoses are a different matter. Chronic AMPK hyperactivation suppresses mTORC1 and downstream protein synthesis. Sustained mTOR suppression impairs muscle hypertrophy, wound healing, and immune function [8]. Patients who discover they have been inadvertently overdosing for weeks should undergo assessment of lean body mass, inflammatory markers, and immune cell counts.

There is no evidence that MOTS-c overdose causes permanent mitochondrial damage. The peptide is an endogenous signaling molecule, produced naturally by human mitochondria, and its receptor interactions are reversible [3]. Once the exogenous peptide clears, cellular signaling returns to baseline.

Poison Control and Reporting

In the United States, the National Poison Control Center (1-800-222-1222) may have limited information on MOTS-c given its status as a non-FDA-approved research compound. Provide the call center with the peptide name, manufacturer, dose administered, and time of exposure.

Because MOTS-c adverse events are not captured by FDA MedWatch (the standard pharmacovigilance reporting system for approved drugs), clinicians who encounter overdose cases should consider publishing case reports in peer-reviewed journals. Each documented case adds to the near-nonexistent safety database for this compound [13].

The Endocrine Society's 2020 position statement on peptide hormones in clinical practice emphasizes that "clinicians prescribing or managing patients using non-FDA-approved peptides bear heightened responsibility for adverse event documentation given the absence of manufacturer pharmacovigilance programs" [14].

When to Go to the Emergency Department

Seek emergency medical care if any of the following occur after suspected MOTS-c overdose:

Blood glucose confirmed below 54 mg/dL or symptoms of neuroglycopenia (confusion, slurred speech, seizure, loss of consciousness).

Persistent vomiting preventing oral carbohydrate intake.

Chest pain, palpitations, or syncope.

Injection-site swelling exceeding 5 cm diameter with fever (suggesting infected injection site rather than peptide-specific toxicity).

Any symptom persisting beyond 6 hours post-injection, which would exceed expected peptide clearance time and suggests either a very large dose or a contaminant-related reaction.

For asymptomatic patients who realize they injected double their usual dose, home monitoring with frequent glucose checks and carbohydrate availability is reasonable, provided they can reach medical care within 15 minutes if symptoms develop.